Induction chemotherapy with cemiplimab in a patient with coexistent vulvar cancer and autoimmune disease: A case report

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports Pub Date : 2024-08-14 DOI:10.1016/j.gore.2024.101487

Elizabeth G. Thayer , M. Larissa Weirich , Zoe A. Roecker , Sara E. Brenner , Jill S. Remick , Ashish B. Patel , Kristen D. Starbuck

{"title":"Induction chemotherapy with cemiplimab in a patient with coexistent vulvar cancer and autoimmune disease: A case report","authors":"Elizabeth G. Thayer , M. Larissa Weirich , Zoe A. Roecker , Sara E. Brenner , Jill S. Remick , Ashish B. Patel , Kristen D. Starbuck","doi":"10.1016/j.gore.2024.101487","DOIUrl":null,"url":null,"abstract":"<div><p>There is limited data regarding the use of immunotherapy for patients with vulvar squamous cell carcinoma and coexisting autoimmune disease. Cemiplimab is a PD-1 inhibitor approved for use in patients with locally advanced and metastatic cutaneous squamous cell carcinoma. However, little is known about its efficacy in the setting of vulvar cancer. We present a case of advanced vulvar squamous cell carcinoma treated with induction chemotherapy and immunotherapy with cemiplimab followed by definitive chemoradiation in the setting of multiple autoimmune diseases. She achieved a complete clinical response and experienced no worsening of her autoimmune conditions despite cessation of her immunosuppressants and initiating an immune checkpoint inhibitor. We review existing data on neoadjuvant treatment of vulvar cancer and the use of cemiplimab in genital and inguinal squamous cell carcinomas. Ongoing exploration of cemiplimab’s efficacy in vulvar cancer and safety in immunosuppressed patients is critical.</p></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352578924001668/pdfft?md5=68eb6065ef2373de8e61abafec9c65e6&pid=1-s2.0-S2352578924001668-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352578924001668","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

There is limited data regarding the use of immunotherapy for patients with vulvar squamous cell carcinoma and coexisting autoimmune disease. Cemiplimab is a PD-1 inhibitor approved for use in patients with locally advanced and metastatic cutaneous squamous cell carcinoma. However, little is known about its efficacy in the setting of vulvar cancer. We present a case of advanced vulvar squamous cell carcinoma treated with induction chemotherapy and immunotherapy with cemiplimab followed by definitive chemoradiation in the setting of multiple autoimmune diseases. She achieved a complete clinical response and experienced no worsening of her autoimmune conditions despite cessation of her immunosuppressants and initiating an immune checkpoint inhibitor. We review existing data on neoadjuvant treatment of vulvar cancer and the use of cemiplimab in genital and inguinal squamous cell carcinomas. Ongoing exploration of cemiplimab’s efficacy in vulvar cancer and safety in immunosuppressed patients is critical.

查看原文本刊更多论文

外阴癌与自身免疫性疾病并存患者的诱导化疗与赛昔单抗：病例报告

关于外阴鳞状细胞癌和并存自身免疫性疾病患者使用免疫疗法的数据有限。Cemiplimab是一种PD-1抑制剂，已被批准用于局部晚期和转移性皮肤鳞状细胞癌患者。然而，人们对其在外阴癌中的疗效知之甚少。我们介绍了一例晚期外阴鳞状细胞癌患者，她在患有多种自身免疫性疾病的情况下接受了诱导化疗和塞米普利姆单抗免疫治疗，随后接受了明确的化疗和放疗。尽管她停用了免疫抑制剂并开始使用免疫检查点抑制剂，但她仍获得了完全临床应答，而且自身免疫性疾病没有恶化。我们回顾了外阴癌新辅助治疗的现有数据，以及cemiplimab在生殖器和腹股沟鳞状细胞癌中的应用。继续探索cemiplimab对外阴癌的疗效以及对免疫抑制患者的安全性至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic Oncology Reports OBSTETRICS & GYNECOLOGY-

CiteScore

2.00

自引率

0.00%

发文量

183

审稿时长

41 days

期刊介绍： Gynecologic Oncology Reports is an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, case series, letters to the editor regarding previously published manuscripts and other short communications in the field of gynecologic oncology. The journal will consider papers that concern tumors of the female reproductive tract, with originality, quality, and clarity the chief criteria of acceptance.